Pathway-specific conditional prognosis after definitive local therapy in stage III non-small cell lung cancer: a single-center retrospective landmark cohort study

AIMS: To describe conditional prognosis after redirection from neoadjuvant immunochemotherapy to definitive radiotherapy in stage III non-small cell lung cancer. PATIENTS AND METHODS: This single-center retrospective study estimated noncausal prognosis in 116 selected patients alive and progression-free 42 days after local treatment: neoadjuvant immunochemotherapy followed by redirected definitive thoracic radiotherapy (NICT-dCRT; n = 36; concurrent chemotherapy in 35), definitive concurrent chemoradiotherapy with consolidation immunotherapy (CRT-CI; n = 43), or surgery after neoadjuvant immunochemotherapy (NICT-S; n = 37). Progression-free survival (PFS) was primary; overall survival (OS) was secondary. Kaplan-Meier and restricted mean survival time (RMST) summaries were emphasized; Firth Cox associations were secondary and exploratory. Overlap weighting failed to achieve adequate balance. RESULTS: In NICT-dCRT and CRT-CI, median OS was 36.5 and 34.0 months, and median PFS was 17.1 and 13.4 months. Corresponding 24-month OS RMST was 20.59 and 20.86 months; PFS RMST was 16.63 and 15.24 months. Between-pathway RMST differences were imprecise. NICT-S had five PFS events and two deaths. CONCLUSIONS: These estimates describe pathway-specific conditional prognosis in clinically distinct post-landmark populations. Clinical selection, sparse events, and residual confounding preclude treatment-superiority or equivalence claims.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-11-17
DOI
https://doi.org/10.1080/14796694.2026.2763318
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pathway-specific conditional prognosis after definitive local therapy in stage III non-small cell lung cancer: a single-center retrospective landmark cohort study

Dong Qian, Zilong Xu, Xiaoyang Li, Mengya Jian et al.
3 links
Future Oncology
Lung Cancer Diagnosis and Treatment
article

Pathway-specific conditional prognosis after definitive local therapy in stage III non-small cell lung cancer: a single-center retrospective landmark cohort study

Dong Qian, Zilong Xu, Xiaoyang Li, Mengya Jian, Yan Li, Weiye Chang
article en

Abstract

AIMS: To describe conditional prognosis after redirection from neoadjuvant immunochemotherapy to definitive radiotherapy in stage III non-small cell lung cancer. PATIENTS AND METHODS: This single-center retrospective study estimated noncausal prognosis in 116 selected patients alive and progression-free 42 days after local treatment: neoadjuvant immunochemotherapy followed by redirected definitive thoracic radiotherapy (NICT-dCRT; n = 36; concurrent chemotherapy in 35), definitive concurrent chemoradiotherapy with consolidation immunotherapy (CRT-CI; n = 43), or surgery after neoadjuvant immunochemotherapy (NICT-S; n = 37). Progression-free survival (PFS) was primary; overall survival (OS) was secondary. Kaplan-Meier and restricted mean survival time (RMST) summaries were emphasized; Firth Cox associations were secondary and exploratory. Overlap weighting failed to achieve adequate balance. RESULTS: In NICT-dCRT and CRT-CI, median OS was 36.5 and 34.0 months, and median PFS was 17.1 and 13.4 months. Corresponding 24-month OS RMST was 20.59 and 20.86 months; PFS RMST was 16.63 and 15.24 months. Between-pathway RMST differences were imprecise. NICT-S had five PFS events and two deaths. CONCLUSIONS: These estimates describe pathway-specific conditional prognosis in clinically distinct post-landmark populations. Clinical selection, sparse events, and residual confounding preclude treatment-superiority or equivalence claims.

Future Oncology
University of Science and Technology of China (CN)
University of Science and Technology of China
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon